Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
Jan 29, 2018 12:00 pm UTC| Business
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone for...
Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018
Jan 29, 2018 12:00 pm UTC| Business
CARMIEL,Israel, Jan. 29, 2018 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company will participate in the 14th Annual WORLDSymposium™ 2018 taking place February 5 – 8, 2018 at...
Targa Resources Announces New Natural Gas Processing Arrangement
Jan 29, 2018 12:00 pm UTC| Business
HOUSTON, Jan. 29, 2018 -- Targa Resources Corp. (NYSE:TRGP) ("Targa" or the "Company"), announced today that it has entered into an agreement to expand its natural gas processing joint venture with MPLX, LP (NYSE:MPLX)...
Eastmain Announces Appointment of Tamara Brown to Board of Directors
Jan 29, 2018 12:00 pm UTC| Business
TORONTO, Jan. 29, 2018 -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EANRF) is pleased to announce the appointment of Tamara Brown to the Board of Directors. Ms. Brown is a mining industry...
Atlantic Capital Bancshares, Inc. Reports Fourth Quarter and Full Year 2017 Results
Jan 29, 2018 12:00 pm UTC| Business
ATLANTA, Jan. 29, 2018 -- Atlantic Capital Bancshares, Inc. (NASDAQ:ACBI) announced a loss of $15.3 million, or ($0.59) per diluted share for the fourth quarter of 2017, compared to net income of $4.0 million, or $0.16...
Fond du Lac’s Annual Sturgeon Spectacular – Big Fish and Really Big Fun
Jan 29, 2018 12:00 pm UTC| Business
FOND DU LAC, Wis., Jan. 29, 2018 -- The Community of Fond du Lac comes together again February 9-11 2018, to host what has quickly become a region-wide midwinter classic, the 3rd Annual Sturgeon Spectacular! This...
Jan 29, 2018 12:00 pm UTC| Business
La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and orally active dual PI3K delta/gamma...